{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T09:49:46Z","timestamp":1774604986806,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2011,1,27]],"date-time":"2011-01-27T00:00:00Z","timestamp":1296086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                        <jats:title>Introduction<\/jats:title>\n                        <jats:p>With the development of increasing numbers of potential therapeutic agents in inflammatory disease comes the need for effective biomarkers to help screen for drug efficacy and optimal dosing regimens early in the clinical trial process. This need has been recognized by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) group, which has established guidelines for biomarker validation. To seek a candidate synovial biomarker of treatment response in psoriatic arthritis (PsA), we determined whether changes in immunohistochemical markers of synovial inflammation correlate with changes in disease activity scores assessing 28 joints (\u0394DAS28) or magnetic resonance imaging synovitis scores (\u0394MRI) in patients with PsA treated with a biologic agent.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Methods<\/jats:title>\n                        <jats:p>Twenty-five consecutive patients with PsA underwent arthroscopic synovial biopsies and MRI scans of an inflamed knee joint at baseline and 12 weeks after starting treatment with either anakinra (first 10 patients) or etanercept (subsequent 15 patients) in two sequential studies of identical design. DAS28 scores were measured at both time points. Immunohistochemical staining for CD3, CD68 and Factor VIII (FVIII) was performed on synovial samples and scored by digital image analysis (DIA). MRI scans performed at baseline and at 12 weeks were scored for synovitis semi-quantitatively. The \u0394DAS28 of the European League Against Rheumatism good response definition (&gt;1.2) was chosen to divide patients into responder and non-responder groups. Differences between groups (Mann Whitney U test) and correlations between \u0394DAS28 with change in immunohistochemical and MRI synovitis scores (Spearman's rho test) were calculated.<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Results<\/jats:title>\n                        <jats:p>Paired synovial samples and MRI scans were available for 21 patients (8 anakinra, 13 etanercept) and 23 patients (8 anakinra, 15 etanercept) respectively. Change in CD3 (\u0394CD3) and CD68 expression in the synovial sublining layer (\u0394CD68sl) was significantly greater in the disease responders compared to non-responders following treatment (<jats:italic>P<\/jats:italic> = 0.005 and 0.013 respectively). \u0394CD3, but not \u0394CD68 or \u0394FVIII, correlated with both \u0394DAS28 (r = 0.49, <jats:italic>P<\/jats:italic> = 0.025) and \u0394MRI (r = 0.58, <jats:italic>P<\/jats:italic> = 0.009).<\/jats:p>\n                     <\/jats:sec><jats:sec>\n                        <jats:title>Conclusions<\/jats:title>\n                        <jats:p>The correlation of \u0394CD3 with \u0394DAS28 and \u0394MRI following biologic treatment in this cohort contributes to the validation of \u0394CD3 as a synovial biomarker of disease response in PsA, and supports the further evaluation of \u0394CD3 for predictive properties of future clinical outcomes.<\/jats:p>\n                     <\/jats:sec>","DOI":"10.1186\/ar3228","type":"journal-article","created":{"date-parts":[[2011,2,25]],"date-time":"2011-02-25T17:10:39Z","timestamp":1298653839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study"],"prefix":"10.1186","volume":"13","author":[{"given":"Eliza K","family":"Pontifex","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle M","family":"Gerlag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Gogarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marjolein","family":"Vinkenoog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilse","family":"Burgman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Bresnihan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul Peter","family":"Tak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin G","family":"Gibney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas J","family":"Veale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"FitzGerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,27]]},"reference":[{"key":"2985_CR1","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","volume":"42","author":"D Kane","year":"2003","unstructured":"Kane D, Stafford L, Bresnihan B, FitzGerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 2003, 42: 1460-1468. 10.1093\/rheumatology\/keg384.","journal-title":"Rheumatology (Oxford)"},{"key":"2985_CR2","first-page":"1167","volume":"34","author":"DD Gladman","year":"2007","unstructured":"Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, Gottlieb AB, Krueger GG, Nash P, Ritchlin CT, Taylor W, Adebajo A, Braun J, Cauli A, Carneiro S, Choy E, Dijkmans B, Espinoza L, van der Heijde D, Husni E, Lubrano E, McGonagle D, Qureshi A, Soriano ER, Zochling J: Consensus on a core set of domains for psoriatic arthritis. J Rheumatol. 2007, 34: 1167-1170.","journal-title":"J Rheumatol"},{"key":"2985_CR3","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/S0197-2456(01)00153-2","volume":"22","author":"VG De Gruttola","year":"2001","unstructured":"De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL: Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. Control Clin Trials. 2001, 22: 485-502. 10.1016\/S0197-2456(01)00153-2.","journal-title":"Control Clin Trials"},{"key":"2985_CR4","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1136\/ard.2004.029751","volume":"64","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, McInnes IB, Bresnihan B, Tak PP: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2005, 64: 834-838. 10.1136\/ard.2004.029751.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR5","first-page":"620","volume":"34","author":"B Bresnihan","year":"2007","unstructured":"Bresnihan B, Gerlag DM, Rooney T, Smeets TJ, Wijbrandts CA, Boyle D, Fitzgerald O, Kirkham BW, McInnes IB, Smith M, Ulfgren AK, Veale DJ, Tak PP: Synovial macrophages as a biomarker of response to therapeutic intervention in rheumatoid arthritis: standardization and consistency across centers. J Rheumatol. 2007, 34: 620-622.","journal-title":"J Rheumatol"},{"key":"2985_CR6","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1002\/art.20664","volume":"50","author":"DM Gerlag","year":"2004","unstructured":"Gerlag DM, Haringman JJ, Smeets TJ, Zwinderman AH, Kraan MC, Laud PJ, Morgan S, Nash AF, Tak PP: Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum. 2004, 50: 3783-3791. 10.1002\/art.20664.","journal-title":"Arthritis Rheum"},{"key":"2985_CR7","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.3899\/jrheum.090348","volume":"36","author":"B Bresnihan","year":"2009","unstructured":"Bresnihan B, Pontifex E, Thurlings RM, Vinkenoog M, El-Gabalawy H, Fearon U, Fitzgerald O, Gerlag DM, Rooney T, van de Sande MG, Veale D, Vos K, Tak PP: Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol. 2009, 36: 1800-1802. 10.3899\/jrheum.090348.","journal-title":"J Rheumatol"},{"key":"2985_CR8","doi-asserted-by":"crossref","unstructured":"Gladman DD, Landewe R, McHugh NJ, Fitzgerald O, Thaci D, Coates L, Mease PJ, Qureshi AA, Krueger GG, Ritchlin CT, Kavanaugh AF, Garg A: Composite measures in psoriatic arthritis: GRAPPA 2008. J Rheumatol. 37: 453-461. 10.3899\/jrheum.090956.","DOI":"10.3899\/jrheum.090956"},{"key":"2985_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/art.1780380107","volume":"38","author":"ML Prevoo","year":"1995","unstructured":"Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL: Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995, 38: 44-48. 10.1002\/art.1780380107.","journal-title":"Arthritis Rheum"},{"key":"2985_CR10","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1136\/ard.2006.051706","volume":"65","author":"J Fransen","year":"2006","unstructured":"Fransen J, Antoni C, Mease PJ, Uter W, Kavanaugh A, Kalden JR, Van Riel PL: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis. 2006, 65: 1373-1378. 10.1136\/ard.2006.051706.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR11","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1136\/ard.2006.055541","volume":"66","author":"B Vander Cruyssen","year":"2007","unstructured":"Vander Cruyssen B, De Keyser F, Kruithof E, Mielants H, Van den Bosch F: Comparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placebo. Ann Rheum Dis. 2007, 66: 138-140. 10.1136\/ard.2006.055541.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR12","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1136\/ard.2008.091389","volume":"68","author":"AW van Kuijk","year":"2009","unstructured":"van Kuijk AW, Gerlag DM, Vos K, Wolbink G, de Groot M, de Rie MA, Zwinderman AH, Dijkmans BA, Tak PP: A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: Effects of adalimumab treatment on synovial tissue. Ann Rheum Dis. 2009, 68: 1303-1309. 10.1136\/ard.2008.091389.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/art.1780360705","volume":"36","author":"D Veale","year":"1993","unstructured":"Veale D, Yanni G, Rogers S, Barnes L, Bresnihan B, Fitzgerald O: Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993, 36: 893-900. 10.1002\/art.1780360705.","journal-title":"Arthritis Rheum"},{"key":"2985_CR14","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1136\/ard.59.12.945","volume":"59","author":"D Baeten","year":"2000","unstructured":"Baeten D, Demetter P, Cuvelier C, Van Den Bosch F, Kruithof E, Van Damme N, Verbruggen G, Mielants H, Veys EM, De Keyser F: Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis. 2000, 59: 945-953. 10.1136\/ard.59.12.945.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2","volume":"43","author":"CL Danning","year":"2000","unstructured":"Danning CL, Illei GG, Hitchon C, Greer MR, Boumpas DT, McInnes IB: Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 2000, 43: 1244-1256. 10.1002\/1529-0131(200006)43:6<1244::AID-ANR7>3.0.CO;2-2.","journal-title":"Arthritis Rheum"},{"key":"2985_CR16","doi-asserted-by":"publisher","first-page":"R569","DOI":"10.1186\/ar1698","volume":"7","author":"E Kruithof","year":"2005","unstructured":"Kruithof E, Baeten D, De Rycke L, Vandooren B, Foell D, Roth J, Canete JD, Boots AM, Veys EM, De Keyser F: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R569-580. 10.1186\/ar1698.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR17","first-page":"198","volume":"25","author":"M Boers","year":"1998","unstructured":"Boers M, Brooks P, Strand CV, Tugwell P: The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol. 1998, 25: 198-199.","journal-title":"J Rheumatol"},{"key":"2985_CR18","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/kem222","volume":"46","author":"CE Vergunst","year":"2007","unstructured":"Vergunst CE, Gerlag DM, Dinant H, Schulz L, Vinkenoog M, Smeets TJ, Sanders ME, Reedquist KA, Tak PP: Blocking the receptor for C5a in patients with rheumatoid arthritis does not reduce synovial inflammation. Rheumatology (Oxford). 2007, 46: 1773-1778. 10.1093\/rheumatology\/kem222.","journal-title":"Rheumatology (Oxford)"},{"key":"2985_CR19","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1002\/art.23591","volume":"58","author":"CE Vergunst","year":"2008","unstructured":"Vergunst CE, Gerlag DM, Lopatinskaya L, Klareskog L, Smith MD, van den Bosch F, Dinant HJ, Lee Y, Wyant T, Jacobson EW, Baeten D, Tak PP: Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 2008, 58: 1931-1939. 10.1002\/art.23591.","journal-title":"Arthritis Rheum"},{"key":"2985_CR20","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/1529-0131(199804)41:4<694::AID-ART17>3.0.CO;2-#","volume":"41","author":"D McGonagle","year":"1998","unstructured":"McGonagle D, Gibbon W, O'Connor P, Green M, Pease C, Emery P: Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum. 1998, 41: 694-700. 10.1002\/1529-0131(199804)41:4<694::AID-ART17>3.0.CO;2-#.","journal-title":"Arthritis Rheum"},{"key":"2985_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1093\/rheumatology\/kel214","volume":"46","author":"AL Tan","year":"2007","unstructured":"Tan AL, Benjamin M, Toumi H, Grainger AJ, Tanner SF, Emery P, McGonagle D: The relationship between the extensor tendon enthesis and the nail in distal interphalangeal joint disease in psoriatic arthritis--a high-resolution MRI and histological study. Rheumatology (Oxford). 2007, 46: 253-256. 10.1093\/rheumatology\/kel214.","journal-title":"Rheumatology (Oxford)"},{"key":"2985_CR22","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006, 54: 2665-2673. 10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"key":"2985_CR23","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/art.1780390105","volume":"39","author":"AM van Gestel","year":"1996","unstructured":"van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL: Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization\/International League Against Rheumatism Criteria. Arthritis Rheum. 1996, 39: 34-40. 10.1002\/art.1780390105.","journal-title":"Arthritis Rheum"},{"key":"2985_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","volume":"356","author":"PJ Mease","year":"2000","unstructured":"Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000, 356: 385-390. 10.1016\/S0140-6736(00)02530-7.","journal-title":"Lancet"},{"key":"2985_CR25","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1136\/ard.60.3.296","volume":"60","author":"MC Kraan","year":"2001","unstructured":"Kraan MC, Smith MD, Weedon H, Ahern MJ, Breedveld FC, Tak PP: Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis. Ann Rheum Dis. 2001, 60: 296-298. 10.1136\/ard.60.3.296.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR26","doi-asserted-by":"publisher","first-page":"R862","DOI":"10.1186\/ar1757","volume":"7","author":"JJ Haringman","year":"2005","unstructured":"Haringman JJ, Vinkenoog M, Gerlag DM, Smeets TJ, Zwinderman AH, Tak PP: Reliability of computerized image analysis for the evaluation of serial synovial biopsies in randomized controlled trials in rheumatoid arthritis. Arthritis Res Ther. 2005, 7: R862-867. 10.1186\/ar1757.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR27","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/rheumatology\/kei094","volume":"44","author":"LA Rhodes","year":"2005","unstructured":"Rhodes LA, Grainger AJ, Keenan AM, Thomas C, Emery P, Conaghan PG: The validation of simple scoring methods for evaluating compartment-specific synovitis detected by MRI in knee osteoarthritis. Rheumatology (Oxford). 2005, 44: 1569-1573. 10.1093\/rheumatology\/kei094.","journal-title":"Rheumatology (Oxford)"},{"key":"2985_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1002\/art.21914","volume":"54","author":"E Kruithof","year":"2006","unstructured":"Kruithof E, De Rycke L, Vandooren B, De Keyser F, FitzGerald O, McInnes I, Tak PP, Bresnihan B, Veys EM, Baeten D: Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis. Arthritis Rheum. 2006, 54: 1795-1804. 10.1002\/art.21914.","journal-title":"Arthritis Rheum"},{"key":"2985_CR29","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/ard.2005.050963","volume":"65","author":"AW van Kuijk","year":"2006","unstructured":"van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP: Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006, 65: 1551-1557. 10.1136\/ard.2005.050963.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR30","doi-asserted-by":"publisher","first-page":"R359","DOI":"10.1186\/ar1501","volume":"7","author":"D Baeten","year":"2005","unstructured":"Baeten D, Kruithof E, De Rycke L, Boots AM, Mielants H, Veys EM, De Keyser F: Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther. 2005, 7: R359-369. 10.1186\/ar1501.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/ard.2003.018549","volume":"64","author":"E Kruithof","year":"2005","unstructured":"Kruithof E, Baeten D, Van den Bosch F, Mielants H, Veys EM, De Keyser F: Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis. 2005, 64: 529-536. 10.1136\/ard.2003.018549.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR32","doi-asserted-by":"publisher","first-page":"3898","DOI":"10.1002\/art.21426","volume":"52","author":"E Kruithof","year":"2005","unstructured":"Kruithof E, De Rycke L, Roth J, Mielants H, Van den Bosch F, De Keyser F, Veys EM, Baeten D: Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum. 2005, 52: 3898-3909. 10.1002\/art.21426.","journal-title":"Arthritis Rheum"},{"key":"2985_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/ard.2003.018085","volume":"63","author":"AY Goedkoop","year":"2004","unstructured":"Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Tak PP: Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis. 2004, 63: 769-773. 10.1136\/ard.2003.018085.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR34","doi-asserted-by":"publisher","first-page":"2776","DOI":"10.1002\/art.10543","volume":"46","author":"MC Kraan","year":"2002","unstructured":"Kraan MC, van Kuijk AW, Dinant HJ, Goedkoop AY, Smeets TJ, de Rie MA, Dijkmans BA, Vaishnaw AK, Bos JD, Tak PP: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002, 46: 2776-2784. 10.1002\/art.10543.","journal-title":"Arthritis Rheum"},{"key":"2985_CR35","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1002\/art.20518","volume":"50","author":"D Kane","year":"2004","unstructured":"Kane D, Gogarty M, O'Leary J, Silva I, Bermingham N, Bresnihan B, Fitzgerald O: Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum. 2004, 50: 3286-3295. 10.1002\/art.20518.","journal-title":"Arthritis Rheum"},{"key":"2985_CR36","doi-asserted-by":"publisher","first-page":"R326","DOI":"10.1186\/ar1182","volume":"6","author":"AY Goedkoop","year":"2004","unstructured":"Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, Tak PP: Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther. 2004, 6: R326-334. 10.1186\/ar1182.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR37","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/art.20181","volume":"50","author":"JD Canete","year":"2004","unstructured":"Canete JD, Pablos JL, Sanmarti R, Mallofre C, Marsal S, Maymo J, Gratacos J, Mezquita J, Mezquita C, Cid MC: Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 2004, 50: 1636-1641. 10.1002\/art.20181.","journal-title":"Arthritis Rheum"},{"key":"2985_CR38","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","volume":"117","author":"D Tracey","year":"2008","unstructured":"Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP: Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008, 117: 244-279. 10.1016\/j.pharmthera.2007.10.001.","journal-title":"Pharmacol Ther"},{"key":"2985_CR39","first-page":"1117","volume":"26","author":"P Costello","year":"1999","unstructured":"Costello P, Bresnihan B, O'Farrelly C, FitzGerald O: Predominance of CD8+ T lymphocytes in psoriatic arthritis. J Rheumatol. 1999, 26: 1117-1124.","journal-title":"J Rheumatol"},{"key":"2985_CR40","first-page":"1544","volume":"25","author":"C Ritchlin","year":"1998","unstructured":"Ritchlin C, Haas-Smith SA, Hicks D, Cappuccio J, Osterland CK, Looney RJ: Patterns of cytokine production in psoriatic synovium. J Rheumatol. 1998, 25: 1544-1552.","journal-title":"J Rheumatol"},{"key":"2985_CR41","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/S0198-8859(99)00034-8","volume":"60","author":"I Tassiulas","year":"1999","unstructured":"Tassiulas I, Duncan SR, Centola M, Theofilopoulos AN, Boumpas DT: Clonal characteristics of T cell infiltrates in skin and synovium of patients with psoriatic arthritis. Hum Immunol. 1999, 60: 479-491. 10.1016\/S0198-8859(99)00034-8.","journal-title":"Hum Immunol"},{"key":"2985_CR42","first-page":"586","volume":"13","author":"DD Gladman","year":"1986","unstructured":"Gladman DD, Anhorn KA, Schachter RK, Mervart H: HLA antigens in psoriatic arthritis. J Rheumatol. 1986, 13: 586-592.","journal-title":"J Rheumatol"},{"key":"2985_CR43","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1093\/rheumatology\/38.1.89","volume":"38","author":"T Daikeler","year":"1999","unstructured":"Daikeler T, Gunaydin I, Einsele H, Kanz L, Kotter I: Transmission of psoriatic arthritis by allogeneic bone marrow transplantation for chronic myelogenous leukaemia from an HLA-identical donor. Rheumatology (Oxford). 1999, 38: 89-90. 10.1093\/rheumatology\/38.1.89.","journal-title":"Rheumatology (Oxford)"},{"key":"2985_CR44","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/j.1365-2133.1997.tb03715.x","volume":"137","author":"JA Snowden","year":"1997","unstructured":"Snowden JA, Heaton DC: Development of psoriasis after syngeneic bone marrow transplant from psoriatic donor: further evidence for adoptive autoimmunity. Br J Dermatol. 1997, 137: 130-132. 10.1111\/j.1365-2133.1997.tb03715.x.","journal-title":"Br J Dermatol"},{"key":"2985_CR45","first-page":"589","volume":"13","author":"A Spadaro","year":"1995","unstructured":"Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol. 1995, 13: 589-593.","journal-title":"Clin Exp Rheumatol"},{"key":"2985_CR46","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","volume":"373","author":"A Gottlieb","year":"2009","unstructured":"Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, Fretzin S, Kunynetz R, Kavanaugh A: Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009, 373: 633-640. 10.1016\/S0140-6736(09)60140-9.","journal-title":"Lancet"},{"key":"2985_CR47","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1002\/art.21870","volume":"54","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Gladman DD, Keystone EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006, 54: 1638-1645. 10.1002\/art.21870.","journal-title":"Arthritis Rheum"},{"key":"2985_CR48","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/ar1934","volume":"8","author":"F McQueen","year":"2006","unstructured":"McQueen F, Lassere M, Ostergaard M: Magnetic resonance imaging in psoriatic arthritis: a review of the literature. Arthritis Res Ther. 2006, 8: 207-10.1186\/ar1934.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR49","first-page":"852","volume":"34","author":"M Ostergaard","year":"2007","unstructured":"Ostergaard M, McQueen F, Bird P, Peterfy C, Haavardsholm E, Ejbjerg B, Lassere M, O'Connor P, Emery P, Edmonds J, Genant H, Conaghan PG: The OMERACT Magnetic Resonance Imaging Inflammatory Arthritis Group - advances and priorities. J Rheumatol. 2007, 34: 852-853.","journal-title":"J Rheumatol"},{"key":"2985_CR50","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3899\/jrheum.090352","volume":"36","author":"M Ostergaard","year":"2009","unstructured":"Ostergaard M, McQueen F, Wiell C, Bird P, Boyesen P, Ejbjerg B, Peterfy C, Gandjbakhch F, Duer-Jensen A, Coates L, Haavardsholm EA, Hermann KG, Lassere M, O'Connor P, Emery P, Genant H, Conaghan PG: The OMERACT psoriatic arthritis magnetic resonance imaging scoring system (PsAMRIS): definitions of key pathologies, suggested MRI sequences, and preliminary scoring system for PsA Hands. J Rheumatol. 2009, 36: 1816-1824. 10.3899\/jrheum.090352.","journal-title":"J Rheumatol"},{"key":"2985_CR51","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/art.10671","volume":"47","author":"C Antoni","year":"2002","unstructured":"Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, Kalden-Nemeth D, Kalden JR, Manger B: Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002, 47: 506-512. 10.1002\/art.10671.","journal-title":"Arthritis Rheum"},{"key":"2985_CR52","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1136\/ard.2006.063818","volume":"66","author":"H Marzo-Ortega","year":"2007","unstructured":"Marzo-Ortega H, McGonagle D, Rhodes LA, Tan AL, Conaghan PG, O'Connor P, Tanner SF, Fraser A, Veale D, Emery P: Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. Ann Rheum Dis. 2007, 66: 778-781. 10.1136\/ard.2006.063818.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1136\/ard.59.2.135","volume":"59","author":"M Bollow","year":"2000","unstructured":"Bollow M, Fischer T, Reisshauer H, Backhaus M, Sieper J, Hamm B, Braun J: Quantitative analyses of sacroiliac biopsies in spondyloarthropathies: T cells and macrophages predominate in early and active sacroiliitis- cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis. 2000, 59: 135-140. 10.1136\/ard.59.2.135.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR54","doi-asserted-by":"publisher","first-page":"R143","DOI":"10.1186\/ar2035","volume":"8","author":"H Appel","year":"2006","unstructured":"Appel H, Loddenkemper C, Grozdanovic Z, Ebhardt H, Dreimann M, Hempfing A, Stein H, Metz-Stavenhagen P, Rudwaleit M, Sieper J: Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis. Arthritis Res Ther. 2006, 8: R143-10.1186\/ar2035.","journal-title":"Arthritis Res Ther"},{"key":"2985_CR55","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1136\/ard.2008.091876","volume":"68","author":"MH Buch","year":"2009","unstructured":"Buch MH, Boyle DL, Rosengren S, Saleem B, Reece RJ, Rhodes LA, Radjenovic A, English A, Tang H, Vratsanos G, O'Connor P, Firestein GS, Emery P: Mode of action of abatacept in rheumatoid arthritis patients having failed TNF blockade: a histological, gene expression and dynamic MRI pilot study. Ann Rheum Dis. 2009, 68: 1220-1227. 10.1136\/ard.2008.091876.","journal-title":"Ann Rheum Dis"},{"key":"2985_CR56","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1136\/ard.2008.096024","volume":"62","author":"N Dalbeth","year":"2009","unstructured":"Dalbeth N, Smith T, Gray S, Doyle A, Antill P, Lobo M, Robinson E, King A, Cornish J, Shalley G, Gao A, McQueen FM: Cellular characterization of magnetic resonance imaging (MRI) bone edema in rheumatoid arthritis; implications for pathogenesis of erosive disease. Ann Rheum Dis. 2009, 62: 279-282. 10.1136\/ard.2008.096024.","journal-title":"Ann Rheum Dis"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/ar3228\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/ar3228.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T11:02:44Z","timestamp":1728385364000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar3228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,27]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,2]]}},"alternative-id":["2985"],"URL":"https:\/\/doi.org\/10.1186\/ar3228","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,27]]},"assertion":[{"value":"21 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"R7"}}